Osimertinib is the active pharmaceutical ingredient (API) in the cancer medication Tagrisso [1]. It is a tyrosine kinase inhibitor (TKI) used to treat certain types of non-small cell lung cancer (NSCLC) that have specific epidermal growth factor receptor (EGFR) mutations [1][2].
How does Osimertinib work?
Osimertinib is a third-generation EGFR inhibitor designed to target specific EGFR mutations, including exon 19 deletions, L858R substitutions, and T790M resistance mutations [2][3]. By inhibiting these mutated EGFRs, osimertinib blocks signaling pathways that promote cancer cell growth and survival [3].
When does Osimertinib's patent expire?
The patent expiry for osimertinib can vary by region and specific patent. Information on drug patents, including expiry dates, is often tracked by resources like DrugPatentWatch.com [4]. Companies may hold multiple patents covering different aspects of a drug, such as the API itself, its synthesis, or its specific uses.
Who makes Tagrisso (osimertinib)?
Tagrisso, the brand-name medication containing osimertinib API, is developed and marketed by AstraZeneca [1].
What are the clinical uses of Osimertinib?
Osimertinib is indicated for the treatment of adult patients with metastatic EGFR-mutated NSCLC. This includes its use as a first-line treatment for patients with exon 19 deletions or L858R substitutions, and for patients whose disease has progressed on or after previous EGFR-TKI therapy due to the development of T790M resistance mutations [1][2]. It is also used for adjuvant treatment after tumor resection in patients with NSCLC harboring EGFR exon 19 deletions or L858R substitutions [1].
Are there generic versions of Osimertinib available or expected?
The availability of generic versions of osimertinib depends on patent expiries and regulatory approvals. Generic competition typically emerges after primary patents expire and any exclusivities have lapsed. Resources that track drug patents, such as DrugPatentWatch.com, provide detailed information on patent landscapes that can indicate when generic versions might become available [4].
What are the side effects associated with Osimertinib?
Common side effects of osimertinib include diarrhea, rash, dry skin, stomatitis, and fatigue [1]. More serious side effects can include interstitial lung disease or pneumonitis, QT prolongation, and cardiomyopathy [1].
How does Osimertinib compare to other EGFR inhibitors?
Osimertinib is considered a third-generation EGFR inhibitor, distinct from earlier generations like gefitinib and erlotinib. Its design allows it to effectively target both common EGFR mutations and the T790M resistance mutation, which is a common cause of resistance to first and second-generation TKIs [2][3]. This makes it a valuable option for patients who have developed resistance to prior EGFR-targeted therapies.
What is the mechanism of resistance to Osimertinib?
While osimertinib is effective, resistance can develop over time. Common mechanisms of resistance include the acquisition of new EGFR mutations, such as C797S, or activation of bypass signaling pathways [3]. Research is ongoing to understand and overcome these resistance mechanisms.
What is the dosage and administration of Osimertinib?
The recommended dose of osimertinib is 80 mg taken orally once a day [1]. It can be taken with or without food [1].
What regulatory approvals has Osimertinib received?
Osimertinib has received approval from major regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for its indicated uses in NSCLC [1][2].
What is the role of API in drug development?
The API, or active pharmaceutical ingredient, is the biologically active component of a drug responsible for its therapeutic effect. For osimertinib, the API is the molecule that inhibits the target EGFR mutations [1][3]. The quality, purity, and manufacturing process of the API are critical for the safety and efficacy of the final drug product.